4DMedical (ASX:4DX) secured contracts with two industry partners to provide its lung imaging technology to aid in the development of new lung disease therapies, according to a Thursday filing with the Australian bourse.
US-based SMS Biotech will work with the company on their phase one trial for stem cell therapy for the treatment of chronic obstructive pulmonary disease, with the initial contract valued at $40,000, the filing said.
Additionally, a medical device developer will utilize the company's technology to improve the evaluation process for candidates in a clinical trial of a lung implantable device, per the filing.
Shares rose 8% in afternoon trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.